Abstract: A display substrate and a display device are provided. The display substrate includes a display region including light emitting units; the light emitting units are arranged into light emitting unit rows, and the light emitting units in one of the light emitting unit rows are arranged along a first direction; the light emitting units include first light emitting units. In at least part of the display region: distances, in the first direction, between a light emitting region of one first light emitting unit and light emitting regions of two of the first light emitting units adjacent to the one first light emitting units are different, and/or distances, in a second direction, between a light emitting region of one first light emitting units and the light emitting regions of two of the first light emitting units adjacent to the one first light emitting units are different.

Abstract: A display panel (20), a display device and a debugging method thereof are provided. The display panel (20) includes: a base substrate (1), including a display region (A) and a non-display region (B) surrounding the display region (A). the non-display region (B) including a binding region (C) located on one side of the display region (A); and a plurality of sub-pixels (2), located in the display region (A). Areas of pixel aperture regions of the plurality of sub-pixels (2) tend to increase in a direction from the binding region (C) to the display region (A).

Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.

Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.

Abstract: The disclosure provides a method of generating modified T cells from engineered stem cells for use in an autologous or allogeneic setting for engineered immunotherapy. The knockout of endogenous TCR or HLA expression allows for engineering of modified pluripotent stem cells that reduce or eliminate the risk of Graft versus Host Disease (GVHD), provide resistance to elimination by a recipient's T cells and NK cells, and allow for controllable T cell activity. Thus, this method allows the development of T cells with reduced immune reactivity.